Although we investigated for the first time the impact of MS number and LM in four different malignancies (NSCLC, melanoma, urothelial carcinoma, and renal carcinoma), anti-PD(L)1 are currently used in many other kinds of cancer treatment, such as head and neck tumors, colorectal cancers, or hepatocellular carcinoma [35,36]. The gene discussed is CD274; the disease is urothelial carcinoma.